24-28周停用阿司匹林与胎盘生物标志物轨迹:一项随机试验的事后分析
本研究为StopPRE试验的事后纵向二次分析,在西班牙9家产科医院纳入936名早产子痫前期高危孕妇,随机分为24-28周停药组(473例)与持续用药至36周组(463例),比较sFlt-1、PlGF及sFlt-1/PlGF比值轨迹;两组各3483次测量,轨迹无显著差异(原始值分析P值分别为0.662、0.728、0.979)。
要点
- 24-28周停用阿司匹林未改变sFlt-1、PlGF及sFlt-1/PlGF比值的孕期轨迹。
- 两组生物标志物轨迹比较的原始值分析P值分别为0.662、0.728、0.979。
- 该结果可能解释StopPRE试验中停药未增加早产子痫前期风险。
核心结论
- 在早产子痫前期高危女性中,24-28周停用阿司匹林未改变胎盘生物标志物轨迹,这可能解释StopPRE试验中停药未增加早产子痫前期风险。
研究设计与样本
- StopPRE随机试验的事后纵向二次分析,采用重复测量 soluble fms-like tyrosine kinase-1(sFlt-1)、placental growth factor(PlGF)及其比值。
- 西班牙9家产科医院参与;原试验纳入936名基于早孕筛查确定的早产子痫前期高危女性,所有参与者每日服用阿司匹林150 mg直至24-28周随机化。
- 随机化时463名女性分配至持续服用阿司匹林至36周,473名分配至停药。
- 在基线(24-28周)及随访访视(28-32周、32-36周、36周后)测量sFlt-1、PlGF、sFlt-1/PlGF。
- 采用线性混合效应模型(LMM)分析生物标志物随时间轨迹,含治疗与孕龄交互项。
主要发现
- 持续用药组463名与停药组473名参与者中,每种生物标志物各分析3483次测量。
- 两组间sFlt-1、PlGF或sFlt-1/PlGF轨迹无显著差异(原始值分析P值分别为0.662、0.728和0.979)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the trajectories of placental biomarkers throughout pregnancy after aspirin discontinuation at 24-28 weeks with those of a cohort treated until 36 weeks of gestation. DESIGN: A longitudinal secondary analysis of the StopPRE trial, using repeated measures of soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and their ratio. SETTING: Nine maternity hospitals across Spain. POPULATION: The original StopPRE trial included 936 women at high risk for preterm preeclampsia based on first-trimester screening. All participants received aspirin 150 mg daily until randomisation at 24-28 weeks. At that point, 463 women were assigned to continue aspirin until 36 weeks, while 473 were assigned to discontinue it. METHODS: sFlt-1, PlGF, sFlt-1/PlGF were measured at baseline (24-28 weeks) and during follow-up visits at 28-32, 32-36, and after 36 weeks of gestation. Linear mixed-effects models (LMM) with treatment-by-gestational age interaction were used to analyze biomarker trajectories over time. MAIN OUTCOME MEASURES: Differences in trajectories of raw values and multiples of the median for sFlt-1, PlGF, sFlt-1/PlGF between groups. RESULTS: Among 463 participants in the aspirin continuation group and 473 in the discontinuation group, 3483 measurements of each biomarker were analysed. There were no significant differences in the trajectories of sFlt-1, PlGF, or sFlt-1/PlGF between groups (p-values for raw analysis: 0.662, 0.728 and 0.979, respectively). CONCLUSIONS: In women at high risk of preterm preeclampsia, discontinuing aspirin at 24-28 weeks did not alter the trajectories of placental biomarkers. This may explain why stopping aspirin did not increase preterm PE risk in the StopPRE trial.
引用
- Bonacina E, Armengol-Alsina M, Garcia-Manau P, et al. Aspirin Discontinuation at 24-28 Weeks and Placental Biomarker Trajectories: Post Hoc Analysis of a Randomised Trial. BJOG. 2025. PMID: 41017450. doi:10.1111/1471-0528.70040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。